HK1064096A1 - Purine derivatives as a2b adenosine receptor antagonists. - Google Patents
Purine derivatives as a2b adenosine receptor antagonists.Info
- Publication number
- HK1064096A1 HK1064096A1 HK04106852A HK04106852A HK1064096A1 HK 1064096 A1 HK1064096 A1 HK 1064096A1 HK 04106852 A HK04106852 A HK 04106852A HK 04106852 A HK04106852 A HK 04106852A HK 1064096 A1 HK1064096 A1 HK 1064096A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- optionally substituted
- receptor antagonists
- adenosine receptor
- purine derivatives
- sup
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30220801P | 2001-06-29 | 2001-06-29 | |
PCT/US2002/020631 WO2003002566A1 (en) | 2001-06-29 | 2002-06-27 | Purine derivatives as a2b adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1064096A1 true HK1064096A1 (en) | 2005-01-21 |
Family
ID=23166757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04106852A HK1064096A1 (en) | 2001-06-29 | 2004-09-09 | Purine derivatives as a2b adenosine receptor antagonists. |
Country Status (11)
Country | Link |
---|---|
US (2) | US6770651B2 (ja) |
EP (1) | EP1401837B1 (ja) |
JP (1) | JP4335000B2 (ja) |
KR (2) | KR100883292B1 (ja) |
AT (1) | ATE307132T1 (ja) |
CA (1) | CA2451244C (ja) |
DE (1) | DE60206756T2 (ja) |
DK (1) | DK1401837T3 (ja) |
ES (1) | ES2247356T3 (ja) |
HK (1) | HK1064096A1 (ja) |
WO (1) | WO2003002566A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
EP1456209B1 (en) * | 2001-12-18 | 2007-02-28 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
ATE403656T1 (de) * | 2003-05-06 | 2008-08-15 | Cv Therapeutics Inc | Xanthinderivate als a2b- adenosinrezeptorantagonisten |
NL1023355C2 (nl) * | 2003-05-07 | 2004-11-09 | Oce Tech Bv | Hot melt inkt omvattend een mengsel van kleurstoffen. |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
WO2005009445A1 (en) * | 2003-07-22 | 2005-02-03 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
WO2005058898A2 (en) * | 2003-12-16 | 2005-06-30 | Ranbaxy Laboratories Limited | Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
TWI427077B (zh) | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2577514T3 (es) | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP2029597A4 (en) * | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
CA2677733A1 (en) | 2007-02-07 | 2008-09-25 | The Regents Of The University Of California | Conjugates of synthetic tlr agonists and uses therefor |
EP2200615A1 (en) * | 2007-10-16 | 2010-06-30 | Gilead Palo Alto, Inc. | A3 adenosine receptor antagonists |
KR20100137449A (ko) * | 2008-02-07 | 2010-12-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Tlr7 활성화제를 사용한 방광 질환의 치료 |
EP2268641B1 (en) | 2008-03-26 | 2014-09-03 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
US20110118276A1 (en) * | 2008-07-16 | 2011-05-19 | Edward Leung | Methods of treating atherosclerosis |
CN102439011B (zh) * | 2009-02-11 | 2016-05-04 | 加利福尼亚大学校务委员会 | Toll样受体调节剂和疾病的治疗 |
AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
SI2408775T1 (sl) * | 2009-03-20 | 2015-08-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila |
JP5843778B2 (ja) * | 2009-11-09 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物、その調製およびその使用 |
EA201291274A1 (ru) | 2010-06-30 | 2013-12-30 | Джилид Сайэнс, Инк. | Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии |
AU2011303420B2 (en) | 2010-09-13 | 2014-03-20 | Impetis Biosciences Ltd. | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
WO2016087665A2 (en) * | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
CA3021947A1 (en) * | 2016-04-26 | 2017-11-02 | Sumitomo Dainippon Pharma Co., Ltd. | Substituted purine derivative |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
MA55214A (fr) * | 2019-03-05 | 2022-01-12 | F Star Therapeutics Inc | Composés, compositions et procédés pour le traitement d'une maladie |
WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954504A (en) * | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
NZ517546A (en) * | 1999-08-31 | 2003-10-31 | Univ Vanderbilt | Selective antagonists of A2B adenosine receptors |
ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
EP1456209B1 (en) * | 2001-12-18 | 2007-02-28 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
-
2002
- 2002-06-27 US US10/184,494 patent/US6770651B2/en not_active Expired - Fee Related
- 2002-06-27 KR KR1020037017083A patent/KR100883292B1/ko active IP Right Grant
- 2002-06-27 KR KR1020087020714A patent/KR100897219B1/ko active IP Right Grant
- 2002-06-27 ES ES02749704T patent/ES2247356T3/es not_active Expired - Lifetime
- 2002-06-27 AT AT02749704T patent/ATE307132T1/de active
- 2002-06-27 WO PCT/US2002/020631 patent/WO2003002566A1/en active IP Right Grant
- 2002-06-27 JP JP2003508947A patent/JP4335000B2/ja not_active Expired - Lifetime
- 2002-06-27 CA CA2451244A patent/CA2451244C/en not_active Expired - Lifetime
- 2002-06-27 EP EP02749704A patent/EP1401837B1/en not_active Expired - Lifetime
- 2002-06-27 DK DK02749704T patent/DK1401837T3/da active
- 2002-06-27 DE DE60206756T patent/DE60206756T2/de not_active Expired - Lifetime
-
2004
- 2004-04-30 US US10/837,290 patent/US7238700B2/en not_active Expired - Fee Related
- 2004-09-09 HK HK04106852A patent/HK1064096A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2451244C (en) | 2012-01-17 |
ES2247356T3 (es) | 2006-03-01 |
US20040209899A1 (en) | 2004-10-21 |
KR20040023634A (ko) | 2004-03-18 |
ATE307132T1 (de) | 2005-11-15 |
US20030064999A1 (en) | 2003-04-03 |
DK1401837T3 (da) | 2005-11-07 |
DE60206756T2 (de) | 2006-07-13 |
DE60206756D1 (de) | 2006-03-02 |
WO2003002566A1 (en) | 2003-01-09 |
EP1401837B1 (en) | 2005-10-19 |
EP1401837A1 (en) | 2004-03-31 |
US6770651B2 (en) | 2004-08-03 |
JP2004536102A (ja) | 2004-12-02 |
KR20080081208A (ko) | 2008-09-08 |
KR100897219B1 (ko) | 2009-05-14 |
JP4335000B2 (ja) | 2009-09-30 |
US7238700B2 (en) | 2007-07-03 |
KR100883292B1 (ko) | 2009-02-11 |
CA2451244A1 (en) | 2003-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1064096A1 (en) | Purine derivatives as a2b adenosine receptor antagonists. | |
LUC00155I2 (ja) | ||
NL300927I9 (nl) | Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat | |
MXPA04003795A (es) | Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos. | |
WO2003022216A3 (en) | Biaryl substituted purine derivatives as potent antiproliferative agents | |
TW200615265A (en) | Organic compounds | |
MY118904A (en) | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | |
BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
BG106567A (en) | Purine derivatives | |
EP1659111A3 (en) | Piperidine derivatives useful as ccr5 antagonists | |
BG106289A (en) | Purine derivatives | |
RS20050311A (en) | Selected cgrp antagonists,method for production and use thereof as medicament | |
HK1155146A1 (zh) | 作為藥物活性劑的茚衍生物 | |
TW200626145A (en) | Heterocyclic compounds and thrombopoietin receptor activators | |
GEP20104875B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
PL363172A1 (en) | Purine derivatives as purinergic receptor antagonists | |
CA2359646A1 (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method | |
WO2003022219A3 (en) | Biarylamino purine antiproliferative agents | |
WO2006110884A3 (en) | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists | |
WO2003022805A3 (en) | Heterocycle substituted purines as antiproliferative agents | |
GB9908410D0 (en) | Pyridines | |
NZ233015A (en) | Acryloyl-substituted pyrrole derivatives (distamycin a analogues) and pharmaceutical compositions | |
TW333527B (en) | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | |
DE60228817D1 (de) | THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN | |
WO2003068776A1 (fr) | Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220626 |